Clinical Trials Browser

Metastatic Pancreatic Adenocarcinoma × pembrolizumab × Clear all

NCT02907099 2025-02-19

Pembrolizumab and CXCR4 Antagonist BL-8040 in Treating Patients With Metastatic Pancreatic Cancer

Phase 2 Completed

20 enrolled 12 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma

NCT02826486 2024-08-28

COMBAT

Phase 2 Completed

80 enrolled 13 charts

Gastrointestinal

Metastatic Pancreatic Adenocarcinoma